Literature DB >> 25453374

Prognosis of lung cancer patients in Japan according to data from the Japanese Joint Committee of Lung Cancer Registry.

Noriyoshi Sawabata1.   

Abstract

An organ-based lung cancer registry is currently maintained by the Japan Joint Committee of Lung Cancer Registry; this registry contributes to the development of lung cancer treatments and provides TNM classification data. In Japan, the overall 5-year survival rate has improved over time to 52% in 2004; the corresponding rates for each pathologic stage have also improved. Previously, separate registries were maintained for surgical and non-biased cases, whereas a prospective registry for non-surgical cases was added in 2012, and a follow-up examination of those data will be conducted in 2016. In addition, a registry of surgical cases from 2010 will be constructed in 2016. The information provided by these registries should better reveal the status of lung cancer patients in Japan.
Copyright © 2014 The Japanese Respiratory Society. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Japan; Lung cancer; Registry; Survival

Mesh:

Year:  2014        PMID: 25453374     DOI: 10.1016/j.resinv.2014.04.002

Source DB:  PubMed          Journal:  Respir Investig        ISSN: 2212-5345


  11 in total

1.  Outcomes of surgery for lung cancer in patients with atrial fibrillation as a preoperative comorbidity: a decade of experience at a single institution in Japan.

Authors:  Ryu Kanzaki; Toru Kimura; Tomohiro Kawamura; Soichiro Funaki; Yasushi Shintani; Masato Minami; Meinoshin Okumura
Journal:  Surg Today       Date:  2016-11-01       Impact factor: 2.549

2.  Treatment of simultaneously discovered lung cancer and cardiovascular disease: a 20-year single-institution experience.

Authors:  Ryu Kanzaki; Toru Kimura; Tomohiro Kawamura; Soichiro Funaki; Yasushi Shintani; Masato Minami; Shigeru Miyagawa; Koichi Toda; Yoshiki Sawa; Meinoshin Okumura
Journal:  Surg Today       Date:  2016-09-29       Impact factor: 2.549

3.  Clinical Implications of Transbronchial Biopsy for Surgically-resected Non-small Cell Lung Cancer.

Authors:  Motoaki Yasukawa; Noriyoshi Sawabata; Takeshi Kawaguchi; Norikazu Kawai; Shigeki Taniguchi
Journal:  In Vivo       Date:  2018 May-Jun       Impact factor: 2.155

4.  The diagnostic value of serum CEA, NSE and MMP-9 for on-small cell lung cancer.

Authors:  Liu Xu; Wang Lina; Yin Xuejun
Journal:  Open Med (Wars)       Date:  2016-03-26

5.  High preoperative plasma vasohibin-1 concentration predicts better prognosis in patients with non-small cell lung carcinoma.

Authors:  Tatsuaki Watanabe; Tomoko Hosaka; Kaori Ohmori-Matsuda; Yasuhiro Suzuki; Hirotoshi Suzuki; Hiroshi Yabuki; Yasushi Matsuda; Masafumi Noda; Akira Sakurada; Yoshinori Okada; Yasufumi Sato
Journal:  Health Sci Rep       Date:  2018-05-17

6.  Diagnostic efficacy of broncho-alveolar lavage carcino-embronic antigen in carcinoma of lung.

Authors:  Sudarsan Pothal; Kamlesh P Patil; Rekha Manjhi; Pravati Dutta
Journal:  J Family Med Prim Care       Date:  2019-05

7.  High expression of Y-box-binding protein 1 correlates with poor prognosis and early recurrence in patients with small invasive lung adenocarcinoma.

Authors:  Shilei Zhao; Wei Guo; Jinxiu Li; Wendan Yu; Tao Guo; Wuguo Deng; Chundong Gu
Journal:  Onco Targets Ther       Date:  2016-05-05       Impact factor: 4.147

8.  Surgery for non-small cell lung cancer in patients with a history of cardiovascular surgery.

Authors:  Hideyuki Maeda; Masato Kanzaki; Kei Sakamoto; Tamami Isaka; Kenji Yamazaki; Takamasa Onuki
Journal:  Surg Today       Date:  2016-07-21       Impact factor: 2.549

9.  Glutamate-cysteine ligase catalytic subunit is associated with cisplatin resistance in lung adenocarcinoma.

Authors:  Noriko Hiyama; Takahiro Ando; Keita Maemura; Toshio Sakatani; Yosuke Amano; Kousuke Watanabe; Hidenori Kage; Yutaka Yatomi; Takahide Nagase; Jun Nakajima; Daiya Takai
Journal:  Jpn J Clin Oncol       Date:  2018-04-01       Impact factor: 3.019

10.  Incidence and risk factors for pneumonitis among patients with lung cancer who received immune checkpoint inhibitors after palliative thoracic radiotherapy.

Authors:  Satoshi Saito; Takanori Abe; Misaki Iino; Tomomi Aoshika; Yasuhiro Ryuno; Tomohiro Ohta; Mitsunobu Igari; Ryuta Hirai; Yu Kumazaki; Ou Yamaguchi; Kyoichi Kaira; Hiroshi Kagamu; Shin-Ei Noda; Shingo Kato
Journal:  J Radiat Res       Date:  2021-07-10       Impact factor: 2.724

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.